- Vaccine Ontology ID: VO_0004552
- Type: DNA vaccine
- Status: Research
- 1D
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- Vector: pVAC-1D (Reddy et al., 2012)
- Immunization Route: Intramuscular injection (i.m.)
|
- Vaccine Ontology ID: VO_0004551
- Type: DNA vaccine
- Status: Research
- Antigen: the FMDV-specific MEG990 gene - 3 VP1 genes (Dar et al., 2012)
- 1D
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- 1D
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- 1D
gene engineering:
- Type: DNA vaccine construction
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
|
Guinea pig Response
- Vaccination Protocol: Sixty male guinea pigs of 10 weeks of age were divided in to three groups each containing 20 animals. Group I was inoculated with a 10 µg of pVAC- 1D (naked DNA vaccinated group), group II was inoculated with pVAC-1D coated on PLG microparticles (pVAC-1D + PLG group) and group III received PBS. All the animals were inoculated intramuscularly in the gluteal region of the right leg (Reddy et al., 2012).
- Vaccine Immune Response Type: VO_0003057
- Immune Response: Immunization with pVAC 1D-PLG elicited significantly enhanced neutralization antibody responses compared to naked DNA vaccine (Reddy et al., 2012).
- Efficacy: Microparticles coated plasmid DNA-injected guinea pigs were protected when challenged with FMD virus (Reddy et al., 2012).
|
Guinea pig Response
- Vaccination Protocol: Immunization of guinea pigs with the construct at dose rate of 10, 5, 2 and 1 μg per animal was through an intramuscular route (Dar et al., 2012).
- Vaccine Immune Response Type: VO_0003057
- Immune Response: Immune responses included significant neutralizing antibody induction at all doses against all serotypes tested as compared to non-immunized controls, and delayed appearance and reduced severity of FMD lesions (Dar et al., 2012).
- Challenge Protocol: Viral challenge of guinea pigs was 4 week post-immunization with 1000 GPID(50) of FMDV serotype A (Dar et al., 2012).
- Efficacy: Two of six and one of six guinea pigs were completely protected in 10 and 5 μg immunized groups (Dar et al., 2012).
|